SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer's Disease.
Trujillo-Estrada L, Vanderklish PW, Nguyen MMT, Kuang RR, Nguyen C, Huynh E, da Cunha C, Javonillo DI, Forner S, Martini AC, Sarraf ST, Simmon VF, Baglietto-Vargas D, LaFerla FM.
Trujillo-Estrada L, et al. Among authors: sarraf st.
Neurotherapeutics. 2021 Oct;18(4):2468-2483. doi: 10.1007/s13311-021-01143-1. Epub 2021 Nov 4.
Neurotherapeutics. 2021.
PMID: 34738197
Free PMC article.